New cocktail aims to tackle returning brain tumors

NCT ID NCT03743662

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding the immunotherapy drug nivolumab to re-irradiation and bevacizumab can help people with recurrent glioblastoma live longer. The study includes 39 participants whose tumors have a specific genetic marker (MGMT methylated). The goal is to see if this combination is more effective than standard treatments for this aggressive brain cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (a drug that helps the immune system fight cancer)
What this could lead to: If successful, this could offer a new treatment option for people with recurrent glioblastoma, potentially extending survival.
What could go wrong: This is a small, early-phase trial (39 people) with no control group, so results may not be definitive. The combination also carries risks like immune-related side effects and bleeding from bevacizumab.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Hartford Healthcare (Data Collection)

Hartford, Connecticut, 06102, United States
Indiana University (Data Collection Only)

Indianapolis, Indiana, 46202, United States
Lehigh Valley Health Network (Data Collection Only)

Allentown, Pennsylvania, 18103, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
University of Vermont Medical Center (Data Collection Only)

Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.